Patent ID: 6552010
Filing Date: 2003-04-22
Classification: A61K,A61P

Abstract:
A method for determining whether an individual with systemic lupus erythematosus (SLE) is responding to DHEA administration for treatment of SLE, comprising:a) at least about 4 weeks after initiating DHEA administration, determining the following, disease-activity and constitutional-symptom variables characterizing the individual's SLE condition: the SLE Disease Activity Index (SLEDAI), Krupp Fatigue Severity Score (KFSS), the Patient Visual Analog Scale (Patient VAS), and the Systemic Lupus Activity Measurement (SLAM); and b) determining the differences between the values for SLEDAI, KFSS, VAS, and SLAM after initiating DHEA administration and baseline values for SLEDAI, KFSS, VAS, and SLAM before initiating DHEA administration, wherein a decrease in three of these four variables and either a decrease, no change, or an increase of no more than about 5% of a baseline value in the fourth variable indicates that the individual is responding to said DHEA administration.